Report Detail

Request for Sample of this report

Pharma & Healthcare Global Sickle Cell Anemia Therapeutics Market 2026 by Company, Regions, Type and Application, Forecast to 2032

  • RnM4713139
    • |
  • 29 June, 2026
    • |
  • Global
    • |
  • 103 Pages
    • |
  • GIR
    • |
  • Pharma & Healthcare

According to our (Global Info Research) latest study, the global Sickle Cell Anemia Therapeutics market size was valued at US$ 4757 million in 2025 and is forecast to a readjusted size of US$ 11350 million by 2032 with a CAGR of 13.4% during review period.
Sickle cell disease (SCD) is a chronic, inherited blood disorder caused by a mutation in the beta-globin gene, leading to the production of abnormal hemoglobin called sickle hemoglobin (HbS). Under low-oxygen conditions, HbS polymerizes, causing red blood cells to assume a rigid, sickle shape. These deformed cells are prone to hemolysis and can block blood vessels, resulting in pain, anemia, and organ damage. Therapeutic approaches include pharmacological treatments (e.g., hydroxyurea, L-glutamine), gene therapy, hematopoietic stem cell transplantation, and supportive care.
Global Sickle Cell Anemia Therapeutics key players include Emmaus Medical, Theravia, Gamida Cell, GlycoMimetics, etc. Americas is the largest market, with a share about 55%, followed by Europe, and Middle East & Africa, both have a share over 35 percent. In terms of product, Blood Transfusion is the largest segment, with a share over 35%. And in terms of application, the largest application is Child, followed by Adult.The therapeutic landscape for sickle cell disease is rapidly evolving, with major pharmaceutical players (e.g., Pfizer, Novartis, Novo Nordisk) investing alongside specialized biotech firms (e.g., Bluebird Bio, CRISPR Therapeutics, Imara, Emmaus Medical). Approved treatments range from small-molecule agents like L-glutamine (Emmaus) to gene-based curative approaches such as Bluebird’s Zynteglo and CRISPR/Vertex’s Casgevy, marking a shift toward durable, potentially one-time interventions. Future development will prioritize expanding patient access to gene therapies, addressing long-term safety, and improving conditioning regimens for stem cell transplantation. Novel approaches, including anti-adhesion therapies (GlycoMimetics), nitric oxide modulators (Prolong), and macrophage-targeted solutions (Modus), are diversifying the pipeline. With ongoing clinical innovation and supportive regulatory momentum, the field is transitioning from symptomatic relief to functional cures, especially for underserved global populations.
This report is a detailed and comprehensive analysis for global Sickle Cell Anemia Therapeutics market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Sickle Cell Anemia Therapeutics market size and forecasts, in consumption value ($ Million), 2021-2032
Global Sickle Cell Anemia Therapeutics market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Sickle Cell Anemia Therapeutics market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Sickle Cell Anemia Therapeutics market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Sickle Cell Anemia Therapeutics
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Sickle Cell Anemia Therapeutics market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Emmaus Medical, Theravia, Pfizer, Novartis, Bluebird Bio, Novo Nordisk, Gamida Cell, CRISPR Therapeutics, GlycoMimetics, Prolong Pharmaceuticals, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Sickle Cell Anemia Therapeutics market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Blood Transfusion
Pharmacotherapy
Bone Marrow Transplant
Market segment by Application
Child
Adult
Market segment by players, this report covers
Emmaus Medical
Theravia
Pfizer
Novartis
Bluebird Bio
Novo Nordisk
Gamida Cell
CRISPR Therapeutics
GlycoMimetics
Prolong Pharmaceuticals
Modus Therapeutics
Sangamo Biosciences
Bioverativ
Imara
Ironwood Pharmaceuticals
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Sickle Cell Anemia Therapeutics product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Sickle Cell Anemia Therapeutics, with revenue, gross margin, and global market share of Sickle Cell Anemia Therapeutics from 2021 to 2026.
Chapter 3, the Sickle Cell Anemia Therapeutics competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Sickle Cell Anemia Therapeutics market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Sickle Cell Anemia Therapeutics.
Chapter 13, to describe Sickle Cell Anemia Therapeutics research findings and conclusion.


1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Sickle Cell Anemia Therapeutics by Type
    • 1.3.1 Overview: Global Sickle Cell Anemia Therapeutics Market Size by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Global Sickle Cell Anemia Therapeutics Consumption Value Market Share by Type in 2025
    • 1.3.3 Blood Transfusion
    • 1.3.4 Pharmacotherapy
    • 1.3.5 Bone Marrow Transplant
  • 1.4 Global Sickle Cell Anemia Therapeutics Market by Application
    • 1.4.1 Overview: Global Sickle Cell Anemia Therapeutics Market Size by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Child
    • 1.4.3 Adult
  • 1.5 Global Sickle Cell Anemia Therapeutics Market Size & Forecast
  • 1.6 Global Sickle Cell Anemia Therapeutics Market Size and Forecast by Region
    • 1.6.1 Global Sickle Cell Anemia Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
    • 1.6.2 Global Sickle Cell Anemia Therapeutics Market Size by Region, (2021-2032)
    • 1.6.3 North America Sickle Cell Anemia Therapeutics Market Size and Prospect (2021-2032)
    • 1.6.4 Europe Sickle Cell Anemia Therapeutics Market Size and Prospect (2021-2032)
    • 1.6.5 Asia-Pacific Sickle Cell Anemia Therapeutics Market Size and Prospect (2021-2032)
    • 1.6.6 South America Sickle Cell Anemia Therapeutics Market Size and Prospect (2021-2032)
    • 1.6.7 Middle East & Africa Sickle Cell Anemia Therapeutics Market Size and Prospect (2021-2032)

2 Company Profiles

  • 2.1 Emmaus Medical
    • 2.1.1 Emmaus Medical Details
    • 2.1.2 Emmaus Medical Major Business
    • 2.1.3 Emmaus Medical Sickle Cell Anemia Therapeutics Product and Solutions
    • 2.1.4 Emmaus Medical Sickle Cell Anemia Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Emmaus Medical Recent Developments and Future Plans
  • 2.2 Theravia
    • 2.2.1 Theravia Details
    • 2.2.2 Theravia Major Business
    • 2.2.3 Theravia Sickle Cell Anemia Therapeutics Product and Solutions
    • 2.2.4 Theravia Sickle Cell Anemia Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Theravia Recent Developments and Future Plans
  • 2.3 Pfizer
    • 2.3.1 Pfizer Details
    • 2.3.2 Pfizer Major Business
    • 2.3.3 Pfizer Sickle Cell Anemia Therapeutics Product and Solutions
    • 2.3.4 Pfizer Sickle Cell Anemia Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Pfizer Recent Developments and Future Plans
  • 2.4 Novartis
    • 2.4.1 Novartis Details
    • 2.4.2 Novartis Major Business
    • 2.4.3 Novartis Sickle Cell Anemia Therapeutics Product and Solutions
    • 2.4.4 Novartis Sickle Cell Anemia Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Novartis Recent Developments and Future Plans
  • 2.5 Bluebird Bio
    • 2.5.1 Bluebird Bio Details
    • 2.5.2 Bluebird Bio Major Business
    • 2.5.3 Bluebird Bio Sickle Cell Anemia Therapeutics Product and Solutions
    • 2.5.4 Bluebird Bio Sickle Cell Anemia Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Bluebird Bio Recent Developments and Future Plans
  • 2.6 Novo Nordisk
    • 2.6.1 Novo Nordisk Details
    • 2.6.2 Novo Nordisk Major Business
    • 2.6.3 Novo Nordisk Sickle Cell Anemia Therapeutics Product and Solutions
    • 2.6.4 Novo Nordisk Sickle Cell Anemia Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Novo Nordisk Recent Developments and Future Plans
  • 2.7 Gamida Cell
    • 2.7.1 Gamida Cell Details
    • 2.7.2 Gamida Cell Major Business
    • 2.7.3 Gamida Cell Sickle Cell Anemia Therapeutics Product and Solutions
    • 2.7.4 Gamida Cell Sickle Cell Anemia Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Gamida Cell Recent Developments and Future Plans
  • 2.8 CRISPR Therapeutics
    • 2.8.1 CRISPR Therapeutics Details
    • 2.8.2 CRISPR Therapeutics Major Business
    • 2.8.3 CRISPR Therapeutics Sickle Cell Anemia Therapeutics Product and Solutions
    • 2.8.4 CRISPR Therapeutics Sickle Cell Anemia Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 CRISPR Therapeutics Recent Developments and Future Plans
  • 2.9 GlycoMimetics
    • 2.9.1 GlycoMimetics Details
    • 2.9.2 GlycoMimetics Major Business
    • 2.9.3 GlycoMimetics Sickle Cell Anemia Therapeutics Product and Solutions
    • 2.9.4 GlycoMimetics Sickle Cell Anemia Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 GlycoMimetics Recent Developments and Future Plans
  • 2.10 Prolong Pharmaceuticals
    • 2.10.1 Prolong Pharmaceuticals Details
    • 2.10.2 Prolong Pharmaceuticals Major Business
    • 2.10.3 Prolong Pharmaceuticals Sickle Cell Anemia Therapeutics Product and Solutions
    • 2.10.4 Prolong Pharmaceuticals Sickle Cell Anemia Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Prolong Pharmaceuticals Recent Developments and Future Plans
  • 2.11 Modus Therapeutics
    • 2.11.1 Modus Therapeutics Details
    • 2.11.2 Modus Therapeutics Major Business
    • 2.11.3 Modus Therapeutics Sickle Cell Anemia Therapeutics Product and Solutions
    • 2.11.4 Modus Therapeutics Sickle Cell Anemia Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 Modus Therapeutics Recent Developments and Future Plans
  • 2.12 Sangamo Biosciences
    • 2.12.1 Sangamo Biosciences Details
    • 2.12.2 Sangamo Biosciences Major Business
    • 2.12.3 Sangamo Biosciences Sickle Cell Anemia Therapeutics Product and Solutions
    • 2.12.4 Sangamo Biosciences Sickle Cell Anemia Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 Sangamo Biosciences Recent Developments and Future Plans
  • 2.13 Bioverativ
    • 2.13.1 Bioverativ Details
    • 2.13.2 Bioverativ Major Business
    • 2.13.3 Bioverativ Sickle Cell Anemia Therapeutics Product and Solutions
    • 2.13.4 Bioverativ Sickle Cell Anemia Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.13.5 Bioverativ Recent Developments and Future Plans
  • 2.14 Imara
    • 2.14.1 Imara Details
    • 2.14.2 Imara Major Business
    • 2.14.3 Imara Sickle Cell Anemia Therapeutics Product and Solutions
    • 2.14.4 Imara Sickle Cell Anemia Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.14.5 Imara Recent Developments and Future Plans
  • 2.15 Ironwood Pharmaceuticals
    • 2.15.1 Ironwood Pharmaceuticals Details
    • 2.15.2 Ironwood Pharmaceuticals Major Business
    • 2.15.3 Ironwood Pharmaceuticals Sickle Cell Anemia Therapeutics Product and Solutions
    • 2.15.4 Ironwood Pharmaceuticals Sickle Cell Anemia Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.15.5 Ironwood Pharmaceuticals Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Sickle Cell Anemia Therapeutics Revenue and Share by Players (2021-2026)
  • 3.2 Market Share Analysis (2025)
    • 3.2.1 Market Share of Sickle Cell Anemia Therapeutics by Company Revenue
    • 3.2.2 Top 3 Sickle Cell Anemia Therapeutics Players Market Share in 2025
    • 3.2.3 Top 6 Sickle Cell Anemia Therapeutics Players Market Share in 2025
  • 3.3 Sickle Cell Anemia Therapeutics Market: Overall Company Footprint Analysis
    • 3.3.1 Sickle Cell Anemia Therapeutics Market: Region Footprint
    • 3.3.2 Sickle Cell Anemia Therapeutics Market: Company Product Type Footprint
    • 3.3.3 Sickle Cell Anemia Therapeutics Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Sickle Cell Anemia Therapeutics Consumption Value and Market Share by Type (2021-2026)
  • 4.2 Global Sickle Cell Anemia Therapeutics Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

  • 5.1 Global Sickle Cell Anemia Therapeutics Consumption Value Market Share by Application (2021-2026)
  • 5.2 Global Sickle Cell Anemia Therapeutics Market Forecast by Application (2027-2032)

6 North America

  • 6.1 North America Sickle Cell Anemia Therapeutics Consumption Value by Type (2021-2032)
  • 6.2 North America Sickle Cell Anemia Therapeutics Market Size by Application (2021-2032)
  • 6.3 North America Sickle Cell Anemia Therapeutics Market Size by Country
    • 6.3.1 North America Sickle Cell Anemia Therapeutics Consumption Value by Country (2021-2032)
    • 6.3.2 United States Sickle Cell Anemia Therapeutics Market Size and Forecast (2021-2032)
    • 6.3.3 Canada Sickle Cell Anemia Therapeutics Market Size and Forecast (2021-2032)
    • 6.3.4 Mexico Sickle Cell Anemia Therapeutics Market Size and Forecast (2021-2032)

7 Europe

  • 7.1 Europe Sickle Cell Anemia Therapeutics Consumption Value by Type (2021-2032)
  • 7.2 Europe Sickle Cell Anemia Therapeutics Consumption Value by Application (2021-2032)
  • 7.3 Europe Sickle Cell Anemia Therapeutics Market Size by Country
    • 7.3.1 Europe Sickle Cell Anemia Therapeutics Consumption Value by Country (2021-2032)
    • 7.3.2 Germany Sickle Cell Anemia Therapeutics Market Size and Forecast (2021-2032)
    • 7.3.3 France Sickle Cell Anemia Therapeutics Market Size and Forecast (2021-2032)
    • 7.3.4 United Kingdom Sickle Cell Anemia Therapeutics Market Size and Forecast (2021-2032)
    • 7.3.5 Russia Sickle Cell Anemia Therapeutics Market Size and Forecast (2021-2032)
    • 7.3.6 Italy Sickle Cell Anemia Therapeutics Market Size and Forecast (2021-2032)

8 Asia-Pacific

  • 8.1 Asia-Pacific Sickle Cell Anemia Therapeutics Consumption Value by Type (2021-2032)
  • 8.2 Asia-Pacific Sickle Cell Anemia Therapeutics Consumption Value by Application (2021-2032)
  • 8.3 Asia-Pacific Sickle Cell Anemia Therapeutics Market Size by Region
    • 8.3.1 Asia-Pacific Sickle Cell Anemia Therapeutics Consumption Value by Region (2021-2032)
    • 8.3.2 China Sickle Cell Anemia Therapeutics Market Size and Forecast (2021-2032)
    • 8.3.3 Japan Sickle Cell Anemia Therapeutics Market Size and Forecast (2021-2032)
    • 8.3.4 South Korea Sickle Cell Anemia Therapeutics Market Size and Forecast (2021-2032)
    • 8.3.5 India Sickle Cell Anemia Therapeutics Market Size and Forecast (2021-2032)
    • 8.3.6 Southeast Asia Sickle Cell Anemia Therapeutics Market Size and Forecast (2021-2032)
    • 8.3.7 Australia Sickle Cell Anemia Therapeutics Market Size and Forecast (2021-2032)

9 South America

  • 9.1 South America Sickle Cell Anemia Therapeutics Consumption Value by Type (2021-2032)
  • 9.2 South America Sickle Cell Anemia Therapeutics Consumption Value by Application (2021-2032)
  • 9.3 South America Sickle Cell Anemia Therapeutics Market Size by Country
    • 9.3.1 South America Sickle Cell Anemia Therapeutics Consumption Value by Country (2021-2032)
    • 9.3.2 Brazil Sickle Cell Anemia Therapeutics Market Size and Forecast (2021-2032)
    • 9.3.3 Argentina Sickle Cell Anemia Therapeutics Market Size and Forecast (2021-2032)

10 Middle East & Africa

  • 10.1 Middle East & Africa Sickle Cell Anemia Therapeutics Consumption Value by Type (2021-2032)
  • 10.2 Middle East & Africa Sickle Cell Anemia Therapeutics Consumption Value by Application (2021-2032)
  • 10.3 Middle East & Africa Sickle Cell Anemia Therapeutics Market Size by Country
    • 10.3.1 Middle East & Africa Sickle Cell Anemia Therapeutics Consumption Value by Country (2021-2032)
    • 10.3.2 Turkey Sickle Cell Anemia Therapeutics Market Size and Forecast (2021-2032)
    • 10.3.3 Saudi Arabia Sickle Cell Anemia Therapeutics Market Size and Forecast (2021-2032)
    • 10.3.4 UAE Sickle Cell Anemia Therapeutics Market Size and Forecast (2021-2032)

11 Market Dynamics

  • 11.1 Sickle Cell Anemia Therapeutics Market Drivers
  • 11.2 Sickle Cell Anemia Therapeutics Market Restraints
  • 11.3 Sickle Cell Anemia Therapeutics Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Sickle Cell Anemia Therapeutics Industry Chain
  • 12.2 Sickle Cell Anemia Therapeutics Upstream Analysis
  • 12.3 Sickle Cell Anemia Therapeutics Midstream Analysis
  • 12.4 Sickle Cell Anemia Therapeutics Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    Summary:
    Get latest Market Research Reports on Sickle Cell Anemia Therapeutics. Industry analysis & Market Report on Sickle Cell Anemia Therapeutics is a syndicated market report, published as Global Sickle Cell Anemia Therapeutics Market 2026 by Company, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Sickle Cell Anemia Therapeutics market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    		$3,480.00
    		$5,220.00
    		$6,960.00
    		2,690.04
    		4,035.06
    		5,380.08
    		3,239.88
    		4,859.82
    		6,479.76
    		531,361.20
    		797,041.80
    		1,062,722.40
    		293,712.00
    		440,568.00
    		587,424.00
    Credit card Logo
    Sample Question Discount Download PDF

    Related Reports

    Reason to Buy

    • Trusted By Leaders

      Top executives from leading companies purchase research reports from us. 

    • Shop With Confidence

      We assist you with all the pre-sales enquiries related to any report so that you can buy with confidence.

    • Customer Centric

      Need assistance related to your research requirements? We are just a phone call or an email away.

    • Personalized Solutions

      Our experienced research specialists are here to help you locate the right reports for your need.

    • Secure Checkout

      Shop without being worried about safety & security of your transactions.
      •

    Request for Sample of this report

    Reports and Markets

    mcafree

    Contact Us

    +1-352-353-0818 (US)

    info@reportsandmarkets.com

    Support

    EMAIL US

    Newsletter

    KEEP UP TO DATE ON ALL THE LATEST REPORTS


    maxmind_logo